Skip to main content

Third Wave's Shares Rise 28.5 Percent

Shares in Third Wave Technologies rose 28.5 percent for the five-day trading period ended Tuesday. The company’s shares rose 25.25 percent on Tuesday alone.
 
The firm announced after the close of the market on Tuesday that a US District Court in Wisconsin had agreed with its definitions for each of the claims in its patent suit against Digene (see Briefs). News of the decision clearly leaked out to certain investors before Third Wave released the news in a press release.
 
Third Wave led the seven stocks that gained ground for the tracking period. Bruker BioSciences led decliners with a drop of 8.3 percent.
 
Overall, the BCW Index fell 1.2 percent for the week, as stocks across the broader market declined due to a stream of disappointing earnings releases, renewed worries about the mortgage lending market, and profit-taking after the recent gains in the market. The Dow Jones Industrial Average fell 1.8 percent, the Nasdaq dropped 2.7 percent, and the Nasdaq Biotech Index declined 1.7 percent.

 
 
BioCommerce Week Index of Diversified
Molecular Biology Tool Companies
Company
Ticker
Closing Price
(July 24, 2007)
Starting Price
(July 17, 2007)
% change
Affymetrix
AFFX
24.35
26.1
-6.70
Agilent
A
39.19
39.8
-1.53
Applied Biosystems
ABI
32.41
31.91
1.57
Beckman
BEC
67.74
69.07
-1.93
Becton Dickinson
BDX
74.48
75.3
-1.09
Bio-Rad
BIO
78.28
78.13
0.19
Bruker
BRKR
8.02
8.75
-8.34
Caliper
CALP
4.91
4.85
1.24
Cepheid
CPHD
14.85
16.01
-7.25
Illumina
ILMN
41.83
41.87
-0.10
Invitrogen
IVGN
74.89
75.82
-1.23
Luminex
LMNX
13.52
13.17
2.66
MDS
MDZ
20.43
20.55
-0.58
Millipore
MIL
79.38
79.14
0.30
PerkinElmer
PKI
26.85
27.28
-1.58
Qiagen
QGEN
17.42
17.8
-2.13
Sequenom
SQNM
5.06
5.42
-6.64
Sigma-Aldrich
SIAL
44.68
44.19
1.11
Thermo
TMO
51.64
53.73
-3.89
Third Wave
TWTI
7.39
5.75
28.52
Waters
WAT
59.35
61.89
-4.10
BCW Index Average  
37.46
37.93
-1.24
The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.